Literature DB >> 206172

Comparison of the lesions of Aleutian disease in mink and hypergammaglobulinemia in ferrets.

K Ohshima, D T Shen, J B Henson, J R Gorham.   

Abstract

Gross and microscopic lesions of Aleutian disease (AD) in mink and hypergammaglobulinemia in ferrets were compared. Both conditions were characterized by widespread proliferation of plasma cells, but proliferation was more prominent in mink infected with AD. Arteritis did not occur in hypergammaglobulinemic ferrets. Minimal or no glomerular alterations occurred in infected ferrets, but were severe in mink infected with AD. Bile duct proliferation was more prominent in diseased mink. Tissue alterations suggested that AD in Aleutian genotype mink is more rapidly progressive than is AD in ferrets, causing overt clinical disease and death. In contrast, hypergammaglobulinemia in ferrets appeared to progress more slowly, with little clinical evidence of disease. This is probably the result of a paucity of glomerular lesions in ferrets. Possible mechanisms to explain the differences in the development of lesions are discussed.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 206172

Source DB:  PubMed          Journal:  Am J Vet Res        ISSN: 0002-9645            Impact factor:   1.156


  4 in total

1.  Aleutian disease in ferrets.

Authors:  H G Porter; D D Porter; A E Larsen
Journal:  Infect Immun       Date:  1982-04       Impact factor: 3.441

2.  Comparative pathogenicity of four strains of Aleutian disease virus for pastel and sapphire mink.

Authors:  W J Hadlow; R E Race; R C Kennedy
Journal:  Infect Immun       Date:  1983-09       Impact factor: 3.441

Review 3.  Viral diseases of ferrets.

Authors:  Isabelle Langlois
Journal:  Vet Clin North Am Exot Anim Pract       Date:  2005-01

Review 4.  Amdoparvoviruses in small mammals: expanding our understanding of parvovirus diversity, distribution, and pathology.

Authors:  Marta Canuti; Hugh G Whitney; Andrew S Lang
Journal:  Front Microbiol       Date:  2015-10-12       Impact factor: 5.640

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.